Kitov Pharmaceuticals Holdings Ltd (NASDAQ:KTOV) has received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.

Brokerages have set a 1-year consensus price objective of $10.00 for the company, according to Zacks. Zacks has also assigned Kitov Pharmaceuticals an industry rank of 107 out of 265 based on the ratings given to related companies.

Separately, HC Wainwright upgraded shares of Kitov Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $10.00 price objective for the company in a research note on Tuesday, November 21st.

Shares of Kitov Pharmaceuticals (KTOV) traded down $0.10 during midday trading on Friday, reaching $2.21. 93,100 shares of the company’s stock traded hands, compared to its average volume of 238,007. Kitov Pharmaceuticals has a twelve month low of $1.27 and a twelve month high of $3.49.

TRADEMARK VIOLATION NOTICE: This story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at

About Kitov Pharmaceuticals

Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.

Get a free copy of the Zacks research report on Kitov Pharmaceuticals (KTOV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Kitov Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kitov Pharmaceuticals and related companies with's FREE daily email newsletter.